Clinical Trial Update: A Study of MK-2225 in Healthy Participants (MK-2225-003) [Phase 1]

View source ↗

Summary

Phase 1 trial MK-2225-003 in healthy participants has completed, sponsored by Merck Sharp & Dohme LLC, with systemic sclerosis listed as the related condition.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• MK-2225

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Systemic Sclerosis | Phase 1 | Status: COMPLETED